Gilbert N. Miller
Director/Board Member at Artielle ImmunoTherapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Hicks | M | 77 |
Virogenomics BioDevelopment, Inc.
 Virogenomics BioDevelopment, Inc. BiotechnologyHealth Technology Virogenomics BioDevelopment, Inc. develops new drugs for the treatment of human diseases. Its business strategy is to identify and obtain rights to early-stage technologies, manage and develop these technologies to a critical phase, and then spin-off the developed technologies into new start-up companies. The company was founded by Jeffrey King and Renee Shirley in 2001 and is headquartered in Portland, OR. | 23 years |
| Peter C. M. McWilliams | M | - |
Artielle ImmunoTherapeutics, Inc.
 Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
| Jeff King | M | - |
Virogenomics BioDevelopment, Inc.
Virogenomics BioDevelopment, Inc. BiotechnologyHealth Technology Virogenomics BioDevelopment, Inc. develops new drugs for the treatment of human diseases. Its business strategy is to identify and obtain rights to early-stage technologies, manage and develop these technologies to a critical phase, and then spin-off the developed technologies into new start-up companies. The company was founded by Jeffrey King and Renee Shirley in 2001 and is headquartered in Portland, OR. | 23 years |
| Brock Metcalf | M | - |
Virogenomics BioDevelopment, Inc.
Virogenomics BioDevelopment, Inc. BiotechnologyHealth Technology Virogenomics BioDevelopment, Inc. develops new drugs for the treatment of human diseases. Its business strategy is to identify and obtain rights to early-stage technologies, manage and develop these technologies to a critical phase, and then spin-off the developed technologies into new start-up companies. The company was founded by Jeffrey King and Renee Shirley in 2001 and is headquartered in Portland, OR.
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
| Renee Shirley | F | - |
Virogenomics BioDevelopment, Inc.
Virogenomics BioDevelopment, Inc. BiotechnologyHealth Technology Virogenomics BioDevelopment, Inc. develops new drugs for the treatment of human diseases. Its business strategy is to identify and obtain rights to early-stage technologies, manage and develop these technologies to a critical phase, and then spin-off the developed technologies into new start-up companies. The company was founded by Jeffrey King and Renee Shirley in 2001 and is headquartered in Portland, OR. | 23 years |
| Halina Offner | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 20 years |
| Arthur A. Vandenbark | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 20 years |
| James W. Korfhage | M | - |
Virogenomics BioDevelopment, Inc.
Virogenomics BioDevelopment, Inc. BiotechnologyHealth Technology Virogenomics BioDevelopment, Inc. develops new drugs for the treatment of human diseases. Its business strategy is to identify and obtain rights to early-stage technologies, manage and develop these technologies to a critical phase, and then spin-off the developed technologies into new start-up companies. The company was founded by Jeffrey King and Renee Shirley in 2001 and is headquartered in Portland, OR. | - |
| Rob Wiltbank | M | - |
Virogenomics BioDevelopment, Inc.
Virogenomics BioDevelopment, Inc. BiotechnologyHealth Technology Virogenomics BioDevelopment, Inc. develops new drugs for the treatment of human diseases. Its business strategy is to identify and obtain rights to early-stage technologies, manage and develop these technologies to a critical phase, and then spin-off the developed technologies into new start-up companies. The company was founded by Jeffrey King and Renee Shirley in 2001 and is headquartered in Portland, OR. | - |
| Shahab Fatheazam | M | 72 |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 20 years |
| William Newman | M | - |
Virogenomics BioDevelopment, Inc.
Virogenomics BioDevelopment, Inc. BiotechnologyHealth Technology Virogenomics BioDevelopment, Inc. develops new drugs for the treatment of human diseases. Its business strategy is to identify and obtain rights to early-stage technologies, manage and develop these technologies to a critical phase, and then spin-off the developed technologies into new start-up companies. The company was founded by Jeffrey King and Renee Shirley in 2001 and is headquartered in Portland, OR. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Adolph J. Ferro | M | - |
Epitope, Inc.
 Epitope, Inc. Medical SpecialtiesHealth Technology Epitope, Inc, operates through its subsidiaries. The company provides and develops diagnostic tests and devices for the detection of Human immunodeficiency virus (HIV) through its subsidiary. The company's products include OraSure, an oral specimen collection device and EPIblot, a serum-based Western blot confirmatory test kit. The prime customers of the company includes life insurance companies, prison systems, the military, and colleges and universities. The products are marketed in United States, Canada, Europe, Asia, Latin America and other countries. It is located in Beaverton, OR.
Agritope, Inc.
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 11 years |
| Gregory G. Burrows | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
| Denis Burger | M | 80 |
Epitope, Inc.
Epitope, Inc. Medical SpecialtiesHealth Technology Epitope, Inc, operates through its subsidiaries. The company provides and develops diagnostic tests and devices for the detection of Human immunodeficiency virus (HIV) through its subsidiary. The company's products include OraSure, an oral specimen collection device and EPIblot, a serum-based Western blot confirmatory test kit. The prime customers of the company includes life insurance companies, prison systems, the military, and colleges and universities. The products are marketed in United States, Canada, Europe, Asia, Latin America and other countries. It is located in Beaverton, OR. | 9 years |
| Mark V. Allred | M | 67 |
Epitope, Inc.
Epitope, Inc. Medical SpecialtiesHealth Technology Epitope, Inc, operates through its subsidiaries. The company provides and develops diagnostic tests and devices for the detection of Human immunodeficiency virus (HIV) through its subsidiary. The company's products include OraSure, an oral specimen collection device and EPIblot, a serum-based Western blot confirmatory test kit. The prime customers of the company includes life insurance companies, prison systems, the military, and colleges and universities. The products are marketed in United States, Canada, Europe, Asia, Latin America and other countries. It is located in Beaverton, OR. | - |
| John W. Morgan | M | 70 |
Epitope, Inc.
Epitope, Inc. Medical SpecialtiesHealth Technology Epitope, Inc, operates through its subsidiaries. The company provides and develops diagnostic tests and devices for the detection of Human immunodeficiency virus (HIV) through its subsidiary. The company's products include OraSure, an oral specimen collection device and EPIblot, a serum-based Western blot confirmatory test kit. The prime customers of the company includes life insurance companies, prison systems, the military, and colleges and universities. The products are marketed in United States, Canada, Europe, Asia, Latin America and other countries. It is located in Beaverton, OR. | 2 years |
| Andrew S. Goldstein | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 5 years |
| Roger L. Pringle | M | 83 |
Epitope, Inc.
Epitope, Inc. Medical SpecialtiesHealth Technology Epitope, Inc, operates through its subsidiaries. The company provides and develops diagnostic tests and devices for the detection of Human immunodeficiency virus (HIV) through its subsidiary. The company's products include OraSure, an oral specimen collection device and EPIblot, a serum-based Western blot confirmatory test kit. The prime customers of the company includes life insurance companies, prison systems, the military, and colleges and universities. The products are marketed in United States, Canada, Europe, Asia, Latin America and other countries. It is located in Beaverton, OR. | - |
| Mya Thomae | F | - |
Epitope, Inc.
Epitope, Inc. Medical SpecialtiesHealth Technology Epitope, Inc, operates through its subsidiaries. The company provides and develops diagnostic tests and devices for the detection of Human immunodeficiency virus (HIV) through its subsidiary. The company's products include OraSure, an oral specimen collection device and EPIblot, a serum-based Western blot confirmatory test kit. The prime customers of the company includes life insurance companies, prison systems, the military, and colleges and universities. The products are marketed in United States, Canada, Europe, Asia, Latin America and other countries. It is located in Beaverton, OR. | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 19 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gilbert N. Miller
- Personal Network
